Journal article
Ko Un Park, M. Gregory, M. Lustberg, J. Bazan, Chengli Shen, Shoshana M. Rosenberg, V. Blinder, P. Sharma, L. Pusztai, A. Partridge, A. Thompson
2021
2021
Semantic Scholar
DOI
Cite
Cite
APA
Click to copy
Park, K. U., Gregory, M., Lustberg, M., Bazan, J., Shen, C., Rosenberg, S. M., … Thompson, A. (2021). Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer.
Chicago/Turabian
Click to copy
Park, Ko Un, M. Gregory, M. Lustberg, J. Bazan, Chengli Shen, Shoshana M. Rosenberg, V. Blinder, et al. “Abstract SS2-05: Emerging from COVID-19 Pandemic: Provider Perspective on Use of Neoadjuvant Endocrine Therapy (NET) in Early Stage Hormone Receptor Positive Breast Cancer” (2021).
MLA
Click to copy
Park, Ko Un, et al. Abstract SS2-05: Emerging from COVID-19 Pandemic: Provider Perspective on Use of Neoadjuvant Endocrine Therapy (NET) in Early Stage Hormone Receptor Positive Breast Cancer. 2021.
BibTeX Click to copy
@article{ko2021a,
title = {Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer},
year = {2021},
author = {Park, Ko Un and Gregory, M. and Lustberg, M. and Bazan, J. and Shen, Chengli and Rosenberg, Shoshana M. and Blinder, V. and Sharma, P. and Pusztai, L. and Partridge, A. and Thompson, A.}
}
Abstract
IntroductionDuring the coronavirus 2019 (COVID-19) pandemic in USA, NET use has been recommended to allow safe deferral of surgical treatment in early stage, estrogen receptor positive breast cancer (ER+BC). In such circumstances, after NET use there is limited guidance on locoregional treatment, especially with management of the axilla. We aimed to evaluate patterns of care in early stage ER+BC during the first several months of the COVID-19 pandemic.MethodA cross-sectional, 30-item survey was developed using a standardized survey development framework. The survey was administered May 8 - June 12, 2020 to a convenience sample of medical oncologists (MO), radiation oncologists (RO), and surgeons (SO) - breast committee members of two national cooperative groups (Alliance and SWOG) with additional participation through chain referrals. Providers were presented with general questions on NET use before and during the pandemic. They were asked their propensity for omitting axillary lymph node dissection (ALND) after NET if 1 micrometastatic node is found on sentinel lymph node biopsy, based on duration of NET.Results114 providers from 29 US states completed the survey - 42 (37%) MO, 14 (12%) RO, and 58 (51%) SO, the majority (N=73/96, 76%) with practices dedicated ≥ 75% to BC, at NCI designated comprehensive cancer centers 52% (N=48/94) and in large cities (N=49/94, 52%). Prior to COVID-19, most rarely (N=49/107, 46%) or sometimes (N=36, 33%) used NET for early stage ER+BC. Nearly half were willing to delay surgery up to 2 months (46%) and 3 months (21%) without use of NET (Table 1, †p Citation Format: Ko Un Park, Megan E Gregory, Maryam B Lustberg, Jose G Bazan, Chengli Shen, Shoshana M Rosenberg, Victoria S Blinder, Priyanka Sharma, Lajos Pusztai, Ann H Partridge, Alastair Thompson. Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SS2-05.
